[Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
- DOI
- 10.1016/j.purol.2019.04.007
- Published
- 2019 May-Jun
- Container
- Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.purol.2019.04.007,
title = {[Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].},
author = {Baydaroglu E and Eschwège P and Hubert J and El Osta R},
year = {2019},
journal = {Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie},
doi = {10.1016/j.purol.2019.04.007},
url = {https://doi.org/10.1016/j.purol.2019.04.007}
}RIS
TY - JOUR TI - [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?]. AU - Baydaroglu E AU - Eschwège P AU - Hubert J AU - El Osta R PY - 2019 JO - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie DO - 10.1016/j.purol.2019.04.007 UR - https://doi.org/10.1016/j.purol.2019.04.007 ER -
APA
E, B., P, E., J, H., & R, E. O. (2019). [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. https://doi.org/10.1016/j.purol.2019.04.007
Source records
- pubmed · retrieved 2026-09-26T06:57:21.175Z